AllDocs -> cancers

[Frontiers in Bioscience, 1 g56-59, January 1, 1996] 56 OVARIAN CANCER : NATURAL HISTORY AND METASTATIC PATTERN Amadori D., MD, Sansoni E.,MD, Amadori A., MD Department of Medical Oncology- Pierantoni Hospital, Via Forlanini, 34 47100 FORLI’, Italy TABLE OF CONTENTS 1. Abstract 2. Discussion 3. Conclusions 4. References 1. ABSTRACT Ovarian cancer begins at a molecular level, however to date, our knowledge of genetic changes and mechanisms of ovarian tumorigenesis is limited. The natural history of ovarian cancer may depend on different anatomo-clinical and biological factors. In the life history of ovarian cancers the stage, histology, tumor grade, age of the patient and gene abnormalities, both oncogenes (c-myc, H-ra, new) and oncosuppressor genes (p53, in particular), DNA ploidy and steroid receptor status have ...

[Frontiers in Bioscience 2, g20-26, March 15, 1997] 20 CHEMOTHERAPY OF ADVANCED OVARIAN CANCER Martoni A. 1 , Cacciari N., Angelelli B., Zamagni C., Pannuti F. Med. Oncology Division, S.Orsola -Malpighi Hospital, Bologna, Italy TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Chemotherapy of ovarian cancer with platinum-compounds 3.1. Cis-platinum - based chemotherapy 3.2. Carboplatin-based chemotherapy 4. Taxol 4.1. Chemotherapy of ovarian cancer with taxol 4.2. Combination taxol-carboplatin 5. References 1. ABSTRACT Majority of ovarian cancer patients have advanced disease (stage III or IV) at diagnosis and the prognosis of these patients is poor in spite of aggressive surgery. Therefore chemotherapy has gained a fundamental role in the therapeutic approach of ovarian ...

[Frontiers in Bioscience 1, g24-29, 1 December 1996] 24 POTENTIAL ROLE OF GROWTH FACTORS IN OVARIAN CANCER Jasonni VM 1 , Amadori A 2 , Gentile G 2 , Alesi L 2 1 Department of Obstetric and Gynecology, University of Messina. 2 Department of Obstetric and Gynecology, University of Bologna. TABLE OF CONTENTS 1. Abstract. 2. Introduction 2.1 epidermal growth factor (EGF). 2.2 Transforming growth factor alpha (TGF alpha). 2.3 Transforming growth factor beta (TGF beta). 2.4 Insulin-like growth factors (IGFs). 2.5 Fibroblast growth factors (FGFs). 2.6 Macrophage colony stimulating factor (MCSF). 3. Pahtogenesis of ovarian cancer . 4. Oncogenes and ovarian cancer . 5. Conclusion. 6. References. 1. ABSTRACT ...

Progestin Protects Against Ovarian Cancer DURHAM, N.C. -- A new Duke University Medical Center study shows that oral contraceptives with higher levels of progestin seem to reduce a woman's risk of ovarian cancer . The study is featured in the January issue of the Journal of the National Cancer Institute. Oral contraceptives have long been associated with a decreased risk of ovarian cancers. Some studies show that three or more years of oral contraceptive use reduces the risk of developing epithelial ovarian cancer by 30-50 percent, and the decrease in risk grows with the duration of use. While it has been commonly considered that this reduction in risk is based in limiting ovulation, the Duke study, led by Joellen Schildkraut of the Duke Comprehensive Cancer Center, indicates that the progestin levels in the oral contraceptives might be as important as ovulation reduction in the prevention of ...

Genetic Testing for Breast and Ovarian Cancer Susceptibility One of the most heralded developments in the molecular genetics of cancer in recent years has been identification of the BRCA1 and BRCA2 genes responsible for familial breast/ ovarian cancer syndrome. About 10 percent of women with these cancers carry inherited mutations in one of these genes. Carriers have a considerably elevated lifetime risk of developing breast or ovarian cancer , estimated at 50-70 percent and 10-30 percent respectively, and may also be at elevated risk for colon, prostate, fallopian tube, and peritoneal cancers. Discovery of the BRCA genes has produced significant demand for genetic testing. Because both genes are large, and mutations are scattered throughout their entire sequence, scientists face considerable technical challenges in developing reliable, cost-effective tests. Clinicians as well face immense challenges in deciding ...

8th Annual Ovarian Cancer Survivors Retreat ~ for women who are currently undergoing or have completed treatment for ovarian cancer ~ This retreat will include: * workshops * resource information * fabulous food * great entertainment * guest speakers * recreational activities * beautiful cabins * making new friends * networking opportunities * art studio sessions * fireside chats * group discussions Registration fee is $150 per person (registration after July 31, 2004 goes up to $200). Cost includes all accommodations, meals, entertainment and on-site retreat activities. Transportation is not included. Attendees will be accepted on a first come, first serve basis up to a maximum of 56 participants. A portion of each registration fee has been underwritten by the Ovarian Cancer Survivors Foundation through the support of GlaxoSmithKline, ...

FOR IMMEDIATE RELEASE 03/10/03 For more information: shughes@wellnesscommunitytn.org FREE Workshop for Women Living with Ovarian Cancer Brought to you by The Wellness Community Knoxville, TN (March 10, 2003) – The Wellness Community, a national non-profit organization based in Knoxville, will be offering the first program of its kind for women living with ovarian cancer . This FREE “Patient Active Guide to Living with Ovarian Cancer ” will explore new ways to improve the quality of life during and after treatment by discussing ways to empower women to take a proactive approach to fighting the disease. The Patient Active Guide to Living with Ovarian Cancer will be held Saturday, March 22, 2003 from 10:00am to 12-noon and feature speaker, Dennis Scribner, Jr., M.D., a gynecologic oncologist from Southeast Gynecologic Oncology ...

OVACOME FACTSHEET 19 Fertility Issues for Women with Ovarian Cancer As cancer treatments become more successful, the emphasis is hopefully shifting to include long- term quality of life issues for the woman and her family, rather than just focusing on survival. With this in mind, this factsheet covers the complex area of a woman’s fertility and the treatments commonly used to treat ovarian cancer which can affect fertility, sometimes permanently. In my experience as a Specialist Nurse supporting women of all ages undergoing treatment for ovarian cancer , the preservation of fertility appears to be one of the most important considerations for women of childbearing years. Even when a woman has not been planning or considering a pregnancy, or already has a child, when she is faced with the prospect of the cancer treatment threatening her ...

ovarian cancer What Is the Role of Laparascopic Surgery in Ovarian Cancer ? N. Abu-Rustum Memorial Sloan-Kettering Cancer Center, New York, U.S.A. The role of laparoscopy in ovarian cancer surgery may be divided into the following categories: 1- laparoscopic staging of a pparent early ovarian cancer 2- laparoscopic assessment of disease extent and potential for resectability 3- hand-assisted laparoscopy for resection of selected cases of advanced ovarian cancer 4- laparoscopic reassessment, or second-look operation, or rul e out recurrence. Laparoscopic staging of apparent early ovarian cancer may be accomplished in patients where disease appears limited to the adnexa. For example a completely resected complex adnexal mass with intraoperative frozen-section revealing maligna ncy and no obvious limitation to complete laparoscopic staging. Laparoscopic staging may also ...

Menopause and Ovarian Cancer Survivors Dr. Harpham: Another issue that survivors of ovarian cancer deal with is menopause. The ovaries are a key source of female hormones such as estrogen and progesterone. Estrogen is made in other tissues, too, but the loss of the ovaries can lead to significant symptoms related to the sudden loss of female hormones, and estrogen replacement therapy is such a controversial topic nowadays anyway. Annie, you were only 40 when you were put into menopause. Can you tell us about it? Annie: I didn't feel a lot of the effects until probably after the chemo was getting finished and that type of thing. But I remembered my doctor telling me it was important about the calcium supplements, and he gave me some ideas of things like the Tums or getting a calcium pill, or something along that line. And then, he said he could not put me on anything until after my chemo was finished ...

Sandi's Story: Speaking Up for Ovarian Cancer Survivors Dr. Wendy Harpham: Hi, and welcome to the American Cancer Society Cancer Survivors Network®. I'm Dr. Wendy Harpham, your host. In this program, I'll be talking one-on-one with four survivors of ovarian cancer who are in different stages of treatment. As a cancer survivor myself, I am pleased to speak with our guests about: self-advocacy in the medical setting; the effect of illness on family relationships; advocating for ourselves and others, as well as other topics that arise in the course of our discussion. Dr. Wendy Harpham: I'm speaking with Sandi, a 51 year-old survivor from Ontario, Canada. Sandi is married and does not have children. Hi, Sandi. Sandi: Good morning. How are you? Dr. Wendy Harpham: Good. In 1999, you experienced abdominal bloating that didn't go away. You went to a doctor, who referred ...

Brochure More information from http://www.researchandmarkets.com/reports/863 Strategic Perspectives 2001: Ovarian Cancer - Overview of Current and New Developments Description: Strategic Perspectives 2001: Ovarian Cancer - Overview of Current and New Developments, provides comprehensive insight into future changes in the ovarian cancer market, with an overview of the disease and current treatments, followed by in- depth analysis of the ovarian cancer pipeline by development strategy, drug class, region and company type, and concluding with forecasts of the likely impact these new drugs will have on the future market. Contents: EXECUTIVE SUMMARY Scope Datamonitor insight into the ovarian cancer market With the impending genericization of carboplatin and paclitaxel, which currently dominate the pharmacological treatment of ovarian ...

ovarian cancer National Ovarian Cancer Awareness Week February 9 ? 15 Launch 11am MONDAY 10/2/03-;R.A.H. Back Ache Killing You? It could be. In Australia one woman dies of ovarian cancer every 10 hours. She may have had regular breast screens and pap smears but these tests can?t pick this disease up. She feels tired, bloated perhaps had bad period pains and back ache. If the disease had been detected and treated at an early stage there would have been a 90% chance of survival. Sadly she?s one of the 75% of the 1200 cases of ovarian cancer diagnosed each year at an advanced stage. The stats are not on her side. If only she?d been aware of it sooner. Awareness is imperative in the fight against ovarian cancer . National Ovarian Cancer Awareness week will be officially launched by OvCa Australia (the National Ovarian Cancer Network) on Monday 10/2/03 at 11am at Robson Theatre, Level ...

WellBeing’s Ovarian Cancer Awareness Campaign A personal story Many women with personal stories of hope are helping us to spread our message. Pat from Cambridge is one such woman. Just before Christmas in 1999, Pat, now in her fifties, went to her GP with abdominal pains and swelling. She put it down to the fact that she had been a sufferer of endometriosis in the past so didn’t believe it was a real cause for alarm. Pat was then sent to have an ultrasound scan by her GP and was told she had to have surgery very quickly. “I was fortunate the cancer had not spread,” says Pat, “and the operation was followed by chemotherapy as a precaution.” Since then Pat has been very well. She is one of the lucky ones. Often women don’t know they have ovarian cancer until it has progressed too far to be treated. With your help we can raise the awareness of Ovarian Cancer and its ...

Ovarian Cancer Coalition of Greater California 6 th Annual Run/Walk – September 12, 2004 Pledge Form* * Pledges are NOT required for participation. But every dollar helps us fund research for an early detection test. Please bring your completed pledge forms with donations to the registration area the morning of the Run/Walk. Photocopies are accepted. Your cancelled check is your receipt. Run/Walk Participant Name: Address: City: State: Zip: Day Phone: Donors 1. Name: Total $ Address: 2. Name: Total $ Address: 3. Name: Total $ Address: 4. Name: Total $ Address: 5. Name: Total $ Address: 6. Name: Total $ Address: Total Pledges $_ Total Collected $__ ...

Endocrine-Related Cancer (1998) 5 283-291 Endocrine-Related Cancer (1998) 5 283-291 © 1998 Society for Endocrinology Printed in Great Britain 1351-0088/98/005-283 $08.00/0 283 Introduction Ovarian cancer is the most common cause of death from gynaecological malignancy developing in about 1 woman in 70 and killing 1 in 100. Annually, it accounts for about 5000 new cases in the UK and 24 000 in the USA, with approximately 3500 and 13 500 deaths respectively in the same period. The growth and progression of this disease is driven by a variety of regulators including growth factors, hormones and cytokines. Polypeptide growth factors are an important class of signalling molecules which bind to cell surface receptors and initiate intracellular signalling cascades resulting in the activation or repression of specific genes. These events generally result ...

Ovary Cancer survival, incidence and mortality in NSW 1994–2000 44 The Cancer Council NSW Ovarian cancer • The five-year relative survival from ovarian cancer in NSW between 1994 and 2000 was 39.5% • The adjusted relative risk of excess death due to ovarian cancer after shrinking was lower in South Eastern Sydney by 17%, resulting in 29 fewer deaths • An additional 119 patients would be expected to survive to five years after diagnosis in NSW if the State average risk was shifted to the 20 th centile of the distribution • There were 1,852 new cases of ovarian cancer in NSW in 1994 to 1998 and 1,176 deaths • There were no Area Health Services in which the number of new cases of ovarian cancer was different from expected, and there was no area variation in the excess number of deaths from ovarian cancer Table ...

363 American Journal of Epidemiology Copyright © 2002 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 156, No. 4 Printed in U.S.A. DOI: 10.1093/aje/kwf048 Risk Factors for Invasive Epithelial Ovarian Cancer : Results from a Swedish Case-Control Study Tomas Riman 1,2,3 , Paul W. Dickman 2 , Staffan Nilsson 1,3 , Nestor Correia 2 , Hans Nordlinder 4,5 , Cecilia M. Magnusson 2 , and Ingemar R. Persson 2 1 Department of Obstetrics and Gynecology, Falu Hospital, Falun, Sweden. 2 Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden. 3 Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden. 4 Department of Pathology, ...

Abstract. ß-1,4-galactosyltransferase (ß-1,4-GT) has been reported to be activated in ovarian carcinoma cells and an isoform of this enzyme has been used as a tumor marker for ovarian cancer . The present study was undertaken to clarify how ß-1,4-GT affected the cell biological characteristics of ovarian cancer . To this end, we transfected an ovarian tumor cell line with an antisense gene of ß-1,4-GT. Proliferative potential and morphology of the cells transfected with the antisense gene did not differ from those of the control cells. Adhesive potential to the constituents of extracellular matrix was reduced in the antisense gene transfectants. In a nude mouse, the number of peritoneal dissemination foci of the antisense transfectants was smaller than that of the control cells. These results indicated that ß-1,4-GT is closely related to the invasive and metastatic potentials of ...

NOTES ON PHENOXODIOL AND OVARIAN CANCER 10 DECEMBER 2002 Phenoxodiol Regulates Death Receptor Activity Phenoxodiol is a pan-acting anti- cancer drug. That is, it is active against all forms of human cancer tested to date, and it kills cancer cells by inducing apoptosis (programmed cell death). It does this by allowing activation of the death receptors, a characteristic that researchers at Yale described earlier this year. The death receptors are a family of proteins on the surface of all cells that, when activated, lead immediately to the death of the cell. These receptors - Fas, TNFR1, DR3, TRAIL - are activated by the immune system and trigger the cell to self-destruct through a process of auto-digestion, or apoptosis. The death receptors and apoptosis are important to our health, allowing the body’s immune system to kill a cell whenever it is damaged or when it is required to die as part ...

1 OVARIAN CANCER Tally Levy, MD Division of Gynecologic Oncology Dept of Obstetrics and Gynecology Wolfson Medical Center – Holon - Israel Statistics • 5% of all cancers among women • 23% of gynecological cancers • 4 th cause for cancer death in women • 47% of all deaths from gynecological cancers • One out of 56 women will develop ovarian cancer in her life-time • In the US each 45 min a woman dies from ovarian cancer Statistics • Percent probability at birth of ever developing cancer (females, US 1995): All sites 1/3 Breast 1/8 Cervix 1/91 Corpus 1/45 Lung 1/19 Ovary 1/56 Colon-rectum 1/17 Page 2 2 Classification • Neoplasms derived from the coelomic epithelium • Neoplasms ...

KERBRAT P. et al. Electronic Journal of Oncology , 2001, 1 , 32-42 __ © FNCLCC, 2001 Standards, Options and Recommendations: Ovarian cancer P. KERBRAT 1 , C. LHOMMÉ 2 , B. FERVERS 3, 4 , J.P. GUASTALLA 3 , L. THOMAS 5 , N. TOURNEMAINE 6 , J.P. BASUYAU 7 , C. COHEN-SOLAL 8 , P. DUVILLARD 2 , T. BACHELOT 3 , I. RAY 3 , E. VOOG 3 AND J. DAUPLAT 9 1 Centre Eugène Marquis, Rennes 2 Institut Gustave Roussy, Villejuif 3 Centre Léon Bérard, Lyon 4 FNCLCC, Paris 5 Institut Bergonié, Bordeaux 6 Centre Catherine ...

ovarian cancer 11/26/2003 A Phylogenetic 1 A Phylogenetic Method for Identifying a Stage I Ovarian Cancer Signature in the Mass-Spectrum of Serum Proteins Jack K. Horner Science Applications International Corporation P. O. Box 3827 Santa Fe, NM 87501 Email: jack.k.horner@saic.com 11/26/2003 A Phylogenetic 2 Problem and Method Problem: ovarian cancer (OC) can currently be diagnosed only at advanced stages, when prognosis is very poor Objective: find a method that detects OC at a stage at which it can be successfully treated Method (using serum protein mass-spectra) form a set of known cancer , and known non- cancer , spectra; call this the “reference” set merge reference set with unknown spectrum U apply the phylogenetic maximum parsimony method ...